Anti-MAdCAM-1 therapy does not affect immune surveillance in the central nervous system
Olaf Stüve(Southwestern Medical Center), Ken Gorelick(Pfizer (United States)), Séverine Vermeire(KU Leuven), Robert Clare(Pfizer (United States)), William J. Sandborn(University of San Diego), Fabio Cataldi(Pfizer (United States)), Daniel C. Baumgart(University of Alberta), Matthieu Allez(Inserm), Alaa Ahmad(All India Institute of Medical Sciences), Geert D’Haens(Amsterdam University Medical Centers), Mina Hassan‐Zahraee(Pfizer (United States)), Annamarie Kaminski(Pfizer (United States)), Pierre Desreumaux(Active Biotech (Sweden)), Vivek Pradhan(Pfizer (United States)), A. Van Gossum(Université Libre de Bruxelles), John Cheng(Pfizer (United States)), Walter Reinisch(Medical University of Vienna), Harald Vogelsang(Medical University of Vienna)
Cited by 0
Related Papers
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Crohn's disease
|The Lancet|2012|2.1k